This activity is supported by educational grants from Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk.
In case you missed the tweetorial on Twitter “real time” you can review the course material here and earn the same credit.
2) First, a case study: 65M, new onset T2DM, had NSTEMI 1 yr ago and 2 stents. Also HTN, ↑lipids, prior smoker. On atorva, losartan, metoprolol, ASA 81, and ticagrelor 60 BID. His BMI is 33.2 and his VS are o/w WNL . . .— cardio-met (@cardiomet_CE) February 15, 2021
4) And should you initiate metformin prior to an SGLT2 or GLP-1RA?— cardio-met (@cardiomet_CE) February 15, 2021
6) Welcome back to our accredited tweetorial! Re a1c: @TheAACE recommends a target Hba1c of 6.5% for most pts with DM while @AmDiabetesAssn recommends 7%. Both orgs rec personalizing goals based on comorbidities and risk for hypoglycemia . . .— cardio-met (@cardiomet_CE) February 16, 2021
8) Now re metformin: Both @TheAACE and @AmDiabetesAssn recommend initiating either a GLP-1 RA or an SGLT-2i for patients with ASCVD regardless of HbA1c. Either can be used as monotherapy and should be initiated promptly in this patient to reduce the risk for CVD . . .— cardio-met (@cardiomet_CE) February 16, 2021
16) There have been numerous studies of different GLP-1RAs pic.twitter.com/kMZZ3SmDLe— cardio-met (@cardiomet_CE) February 16, 2021
20) So on the basis of these data, the FDA approved 2 GLP-1RAs for adults with T2D+established CVD to ↓ MACE, and 1 GLP-1RA for T2D+est CVD or multiple risk factors. They were, respectively:— cardio-met (@cardiomet_CE) February 16, 2021
22) Welcome back to our accredited tweetorial! The correct answer is a. Liraglutide and semaglutide are both indicated to reduce risk of MACE in pts with DM2 and established CVD. Dulaglutide is indicated to reduce the risk of MACE in patients with T2DM and established CVD . . .— cardio-met (@cardiomet_CE) February 17, 2021
28) Here’s an essential reference resource: pic.twitter.com/xLCpqhGcYo— cardio-met (@cardiomet_CE) February 17, 2021
30) You made it! Free CE/CME! Physicians, pharmacists, nurses: go to https://t.co/RhLfvOu7n0 and claim your credit! I am @RPratleyMD. Follow @cardiomet_CE for more tweetorials! #medtwittter #cardiotwitter— cardio-met (@cardiomet_CE) February 17, 2021